Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06446648 · ClinicalTrials.gov registry record · Early Phase 1
Impact of Intraoperative ICG on Functional Outc in RARP
A Early Phase 1 study of Prostate Adenocarcinoma, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06446648: Recruiting Early Phase 1 study of Prostate Adenocarcinoma, sponsored by University of California, Irvine.
NCT06446648 is a Early Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 400 participants, above the 214-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (87% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06446648, a Early Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function outcomes at 12 months postoperatively.
Primary Outcome
Number of patients who report using no pads or only 1 security pad per day at 3-month post-surgery.
Conditions Studied
Interventions
- DRUG ICG
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2030-07 |
| Phase | Early Phase 1 |
What NCT06446648 shows while recruiting
NCT06446648 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 214-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which ICG is the first listed.
NCT06446648 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06446648 about?
NCT06446648 is a clinical study titled "Impact of Intraoperative ICG on Functional Outc in RARP". This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function ...
What is the current status of trial NCT06446648?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 400 participants. The study started on 2024-07-12. Estimated completion is 2030-07.
What conditions does trial NCT06446648 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06446648?
The interventions under investigation include: ICG (DRUG).
Who is sponsoring clinical trial NCT06446648?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06446648 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06446648's enrollment target sits among peer trials
400 15th of 99 higher than 84 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RECRUITING · Early Phase 1
-
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
RECRUITING · Early Phase 1
-
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
ACTIVE NOT RECRUITING · Early Phase 1
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI